STAT

Social connections first, science second: How biotech’s recipe for success has its limits

The pivotal financial decisions that determine which biotech companies will survive and which will fail are determined largely by social capital — not by science.

When Laura Indolfi set out to launch a biotech in Boston, she had an idea — and little else. She had never run a company before. She had no practical experience in fundraising.

But she was undeterred. In 2014 she founded PanTher Therapeutics, with the goal of turning a postdoctoral side project into a bona-fide drug delivery company.

“I took a leap of faith,” she told STAT.

Through her five-year odyssey, Indolfi learned a fundamental lesson about the biotech world: who you know can be as important — or even more important — as what you want to do.

First, her “leap of faith’’ needed to be backed up with data. But soon, she needed to match it with cold, hard cash. She met with as many venture capitalists as she could fit into her schedule, hoping to find a

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks